Skip to main content
EnglishEN
pdf-header

Beyond 1M Genomes

Project description

DEENESFRITPL

Pan-European initiative to create genome-based health data infrastructure

Personalised medicine brings significant socio-economic benefits, including faster, more accurate diagnostics, the development of pharmacogenomics and the advancement of preventative medicine, resulting in better health and quality of life for patients as well as more efficient national health systems. The EU-funded B1MG project will provide the support and coordination structure for the European 1+ Million Genomes initiative based on the commitment of 20 EU states and Norway to work 'towards access to at least 1 million sequenced genomes in the EU by 2022'. These countries will engage a range of stakeholders to support the creation of a pan-European genome-based health data infrastructure, encompassing data quality and exchange standards, access protocols and legal guidance.

Objective

The Beyond 1 Million Genomes (B1MG) consortium will establish the support and coordination structure for the European 1+ Million Genomes initiative (1+MG), which is based upon the commitment of 20 European Member States and Norway that have signed the Declaration ‘Towards access to at least 1 million sequenced genomes in the EU by 2022’. Collectively, these countries have committed to establish a cross-border federated network of national genome collections associated with phenotypic data, consented for advancing health and medicine practices across Europe. Europe is uniquely placed to take on this challenge and position itself as a global leader in this field.

B1MG will go ‘beyond’ the 1M genome target and ‘beyond’ the 20 signatory countries. The project will collaborate with an array of international initiatives and consult a range of stakeholders to support the creation of a pan-European genome-based health data infrastructure, encompassing data quality and exchange standards, access protocols and legal guidance. Recommendations will be translated to a B1MG maturity level model that provides concrete guidance on the steps required to implement personalised medicine, a healthcare approach that takes into account a person’s genetic make-up, at local, regional and national-scale.

Personalised medicine is expected to bring significant socio-economic benefits, including more efficient national health systems. Faster and more accurate diagnosis, the development of pharmacogenomics and advancement of preventative medicine will lead to better health, quality of life of patients and increased life expectancy. This will be captured in a methodology for economic evaluation, forming the basis of future business-cases for implementation in the health sector.

Fields of science

Programme(s)

Topic(s)

Call for proposal

H2020-SC1-DTH-2018-2020

See other projects for this call

Sub call

H2020-SC1-DTH-2019-2

Funding Scheme

CSA - Coordination and support action

Coordinator

EUROPEAN MOLECULAR BIOLOGY LABORATORY
Net EU contribution
€ 1 145 070,03
Address
Meyerhofstrasse 1
69117 Heidelberg
Germany

See on map
Region
Baden-Württemberg Karlsruhe Heidelberg, Stadtkreis
Activity type
Research Organisations
Links
Other funding
€ 0,00

Participants (36)

Share this page

Download

Last update: 10 March 2023
Record number: 229985

My Booklet

Permalink: /project/id/951724

European Union, 2023